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THE EFFICACY AND COST-EFFECTIVENESS OF EVOLOCUMAB IN THE 
PREVENTION OF CARDIOVASCULAR DISEASE 
KELLY FAHEY 
ABSTRACT 
Heart disease is the leading cause of death in the United States. Hyperlipidemia is a  
predominant risk factor in the development of atherosclerotic cardiovascular disease 
(ASCVD).  The statin drug class is the first line therapeutic for lowering atherogenic low-
density lipoprotein (LDL) levels by competitively inhibiting 3-hydroxyl-3methyl-
glutaryl-coenzyme A (HMGCR) reductase, the rate-limiting enzyme in cholesterol 
biosynthesis. However, there are patients who are unable to achieve desirable LDL levels 
despite statin therapy, such as those with familial hypercholesterolemia or those who are 
statin intolerant. A new therapy was discovered in 2015 to benefit patients with 
uncontrolled LDL levels by inhibiting Proprotein convertase subtilisin-kexin type 9 
(PCSK9), a key protein in LDL receptor metabolism.  Evolocumab (Repatha, AMGEN) 
is a human monoclonal antibody against human PSCK9.  Evolocumab is approved to 
lower LDL-cholesterol in adult patients who have, despite dietary and lifestyle changes 
and maximally tolerated statin dose continued suboptimal lipid levels with either ASCVD 
or Heterozygous Familial Hypercholesterolemia (HeFH). Evolocumab has been shown to 
significantly reduce atherogenic lipid levels and the recent FOURNIER clinical trial 
showed that evolocumab reduces cardiovascular events. However, the high annual cost of 
evolocumab has raised questions as to its cost-effectiveness and role in the prevention 
and treatment of ASCVD.  At the present price levels, this therapy does not appear to be 
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cost-effective with multiple analyses suggesting significant price reduction will be 
necessary before this drug can be used in standard treatment for secondary prevention of 
cardiovascular disease in the United States. 
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INTRODUCTION 
 
 Heart disease is the leading cause of death in both men and women; over 610,000 
people in the United States die annually from cardiovascular disease (Doonan et al., 
2018).  It is calculated that every 40 seconds, an adult dies from a heart attack, stroke, or 
other related cardiovascular disease (CDC, 2016). The American Heart Association 
(AHA) in 2011 predicted that by the year 2035, more than 45% of the United States 
population, more than 131.2 million Americans, would have some form of heart disease 
due to the nation’s inability to combat obesity, poor diet, high blood pressure, rise in 
Type 2 diabetes, and high cholesterol (AHA, 2017).  In addition to a high mortality rate, 
heart disease and stroke can also lead to extreme morbidity including serious illness, 
disability, and a lower quality of life (Doonan et al., 2018). 
The cost of cardiovascular disease to the United States health care system is 
staggering- it is currently the nation’s costliest chronic disease (AHA, 2017). Currently, 
one out of every six health care dollars is spent on the treatment of cardiovascular disease 
(CDC, 2016). Additionally, more than $193.1 billion was spent in 2016 on direct medical 
expenses associated with cardiovascular disease, and another $123.5 billion in 2016 was 
lost due to decreased productivity from premature deaths (CDC, 2016).  The cost of 
cardiovascular disease is only expected to increase; the AHA anticipates a price tag of 
more than $1.1 trillion by the year 2035 (AHA, 2017).  To help improve the nation’s 
cardiovascular health and economic burden of this disease, it is recommended that access 
to quality health care be preserved and expanded, prevention with a focus on lifestyle 
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changes be emphasized, and continued research on treatments to reduce the morbidity 
and mortality associated with cardiovascular disease (AHA, 2017).  
 
SPECIFIC AIMS 
In the first section of this thesis, the importance of lowering low-density 
lipoprotein cholesterol (LDL-C) levels will be explored, including an overview of 
lipoprotein biochemistry pathways and how dysfunction of this system can lead to 
familial hypercholesterolemia (FH) and the development of atherosclerotic 
cardiovascular disease (ASCVD), which is the primary cause of morbidity and mortality 
in western society. Next, the American College of Cardiology (ACC) and American 
Heart Association (AHA) cholesterol level recommendations as well as therapies to 
lower LDL-C will be discussed, including the use of 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase (HMGCR) inhibitors, known as statins, and proprotein convertase 
subtilisin-kexin type 9 (PCSK9) inhibitors, specifically evolocumab.  Evolocumab (trade 
name Repatha) is a human monoclonal immunoglobulin G2 indicated to lower LDL-C 
levels in adult patients who have, in addition to improving their diet, tolerated the 
maximum amount of statins available and are diagnosed with either ASCVD or 
heterozygous familial hypercholesterolemia (HeFH).  
A literature review will discuss key information regarding pharmacologic therapy 
of hyperlipidemia, including the place of PCSK9 inhibitor’s LDL-C lowering properties 
in the prevention of cardiovascular morbidity and mortality, as shown in the 2017 
FOURNIER study. The PCSK9 inhibitor’s efficacy, safety, and proper utilization will be 
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defined. Finally, the implications of the high annual cost of evolocumab in the United 
States will be discussed in terms of it’s current place in clinical therapy. 
 
Lipoprotein Structure and Function 
 
To fully understand the role lipid dysfunction plays in the development of 
atherosclerotic pathology, it is important to review lipoprotein structure and function and 
the effect it has on the cardiovascular system. The following is a brief discussion of the 
biochemistry behind plasma lipoproteins and cholesterol, followed by an explanation of 
two diseases, ASCVD and FH, both associated with dysfunction of the lipoprotein 
pathway. 
Lipoproteins transport lipids through the blood to tissues in concentrations above 
their solubility in body fluids due to their specialized, spherical structure, detailed in 
Figure 1 (Harisa et al., 2014).  The lipoprotein inner core consists of nonpolar 
hydrophobic lipids such as cholesterol ester (CE) and triacylglycerol (TAG), surrounded 
by an amphipathic shell of phospholipids, free cholesterol, and proteins (Harisa et al., 
2014). Special proteins, called apoproteins (Apo), serve as ligands for cell receptors and 
cofactors for enzymes in metabolism (Harisa et al., 2014). 
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Figure 1. Diagram of plasma lipoprotein general structure. The amphipathic molecule 
consists of a polar shell and a nonpolar inner core. Apoproteins serve as enzyme 
cofactors and receptor ligands (Image taken from Harisa et al., 2014).  
 
The function of plasma lipoproteins include supplying TAG to peripheral tissues 
for storage and fuel, distributing TAG and cholesterol for creating signal molecules and 
the cell membrane, as well as assisting with cholesterol homeostasis (Venugopal et al., 
2018). Plasma lipoproteins are classified into five categories based on density and 
diameter as a result of differing protein and lipid concentrations, as shown in Table 1 
(Venugopal et al., 2018). 
 
 
 
 
 
Peripheral 
apoprotein 
(ex. Apo 
C) 
Triacylglycerol 
(TAG) 
Core consists of nonpolar lipids     
(ex. CE and TAG) 
Cholesterol 
ester (CE) 
Integral apoprotein 
(ex. Apo B100) 
Polar lipid shell 
Free cholesterol 
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Table 1. Characteristics of Human Lipoproteins. 
 Chylomicrons VLDL IDL LDL HDL 
Density (g/mL) 
      <0.95 0.95-1.006 
1.006-
1.019 
1.019-
1.063 
1.063-1.210 
Diameter (nm) 75-1,200 30-80 25-35 18-25 5-12 
Composition (%)      
      Protein 2 10 18 25 33 
      Triglycerides 83 50 31 9 8 
      Cholesterol 8 22 29 45 30 
 
Apolipoproteins 
B 48, A1, C1, 
CII, CIII 
B 100, E, 
C1, CII, 
CIII 
B 100, E, 
CI, CII, 
CIII 
B 100 AI, AII, CI, 
CII, CIII, E 
*Lipoproteins are classified according to their lipid and protein content, which also gives them a distinct 
density and size as well as determines their biological function. Lipoproteins include chylomicrons, very-
low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), low-density lipoprotein (LDL) and 
the antiatherogenic high-density lipoprotein (HDL). (Table taken from Venugopal et al., 2018).  
 
 
 
 
The liver, and partially the small intestine, are responsible for regulating TAG and 
cholesterol homeostasis (Cohen, 2009). Cholesterol in the circulation originates from 
either the exogenous or endogenous lipoprotein pathway (Cohen, 2009). The rate of 
cholesterol absorption in the exogenous pathway varies widely in the population; some 
adults absorb 25% of consumed cholesterol while others absorb up to 80% (Cohen, 
2009). To maintain cholesterol balance, the exogenous pathway synthesizes roughly the 
same amount of cholesterol lost in the feces minus the dietary cholesterol (Cohen et al., 
2009). Together, the endogenous and exogenous pathways work to maintain cholesterol 
homeostasis (Cohen, 2009).  
In the exogenous pathway, chylomicrons are assembled from dietary TAG in 
enterocytes and then travel to the systemic circulation where they distribute TAG to 
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peripheral tissues for energy and storage (Feingold et al., 2018). Apo CII on the 
chylomicron surface activates the enzyme lipoprotein lipase (LPL), expressed mainly in 
muscle and adipose capillaries, to catalyze the reaction that hydrolyzes TAG to free fatty 
acids (Feingold et al., 2018). As the chylomicron courses through the periphery, the 
metabolism and removal of TAG from the core results in the gradual loss of Apo CII and 
formation of chylomicron remnants (Venugopal et al., 2018). Chylomicron remnants are 
enriched with CE and gain Apo E while giving up Apo AI and CII to HDL (Feingold et 
al., 2018).  The liver remnant receptor recognizes Apo E and takes up chylomicron 
remnants via receptor-mediated endocytosis (Venugopal et al., 2018). In the hepatocyte, 
dietary cholesterol has four routes for metabolism (Dose et al., 2016). It is secreted 
directly into bile, converted into bile acids and then secreted into bile, esterified and 
stored as CE, or enters the endogenous pathway and is packaged into VLDL and secreted 
into the plasma (Dose et al., 2016). 
In the endogenous pathway, VLDL is created in the liver from excess CE, TAG, 
Apo CII, Apo E, and the core structural protein Apo B-100 (Feingold et al., 2018). VLDL 
travels through the systemic circulation where Apo CII activates LPL on the surface of 
endothelial cells to hydrolyze TAG (Venugopal et al., 2018).  Similar to chylomicron 
metabolism, as TAG is removed from VLDL, remnants, or IDL, are created (Venugopal 
et al., 2018). IDL is cleared by the liver or with continued removal of TAG from IDL, 
metabolized to LDL (Venugopal et al., 2018).  The liver clears approximately 50% of 
IDL (Venugopal et al., 2018). 
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Figure 2. Diagram of exogenous pathway, endogenous pathway, and reverse 
cholesterol transport in humans.  In the exogenous pathway, chylomicrons are created 
in enterocytes from dietary cholesterol and TAG to deliver to peripheral tissues and the 
liver. In the endogenous pathway, VLDL is created from excess cholesterol and 
triglycerides. VLDL is metabolized to LDL, which deposits cholesterol to peripheral 
tissues or is returned to the liver via receptor-mediated endocytosis. In the reverse 
cholesterol transport pathway (RCT), HDL removes excess cholesterol from peripheral 
tissues and returns it to the liver.  (Image taken from Dose et al., 2016) 
 
LDL is the end product of VLDL metabolism (Feingold et al., 2018). LDL 
consists of primarily CE and one structural protein, Apo B-100, which controls LDL 
cholesterol’s interaction with the LDL receptor on hepatocytes as well as peripheral 
tissues such as the adrenal gland, muscle, gonads, and adipose tissue (Feingold et al., 
2018). After internalization, lysosomes degrade the LDL particle, releasing cholesterol 
into the cell, as depicted in Figure 3 (Feingold et al., 2018). 
HDL, characterized by the presence of Apo A1, are synthesized and secreted by 
the liver to remove excess cholesterol from peripheral tissues and return it to the liver for 
further breakdown or excretion (Feingold et al., 2018).  This process of clearing 
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cholesterol from peripheral tissues, importantly vascular tissue, is known as reverse 
cholesterol transport (Feingold et al., 2018). 
The amount of circulating LDL is dependent on two factors: the amount of LDL 
created from VLDL and the rate of LDL clearance from the plasma (Feingold et al., 
2018). Both of these factors are dependent on the number of LDL receptors on 
hepatocytes (Feingold et al., 2018). When there are numerous LDL receptors, more IDL 
is cleared, reducing the amount of LDL created from IDL (Feingold et al., 2018). 
Likewise, where there are few LDL receptors present, less IDL is removed from the 
circulation, so more IDL is metabolized to LDL (Feingold et al., 2018). In terms of the 
clearance of LDL from the plasma, the liver normally removes 70% of LDL (Feingold et 
al., 2018). LDL binds to the LDL receptor on hepatocytes and is taken up through 
endocytosis in clathrin-coated vesicles, which was famously deduced by Goldstein and 
Brown in 1973 (Goldstein and Brown, 1973). The clearance of LDL is also dependent on 
the number of LDL receptors on hepatocytes (Feingold et al., 2018).  An increase in LDL 
receptors increases the clearance of LDL from the plasma; conversely, a decrease in LDL 
receptors decreases the clearance of LDL from the plasma (Feingold et al., 2018). Figure 
3 depicts the LDL receptor pathway and outlines the regulatory actions of increased 
cholesterol in hepatocytes. 
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Figure 3: LDL receptor pathway and regulatory actions in hepatic cells.  Apo B100 
on the surface of LDL binds to LDL receptors on the hepatocyte and activates receptor-
mediated endocytosis forming an endosome. LDL receptors are recycled to the plasma 
membrane at an internal pH of 5.0, and LDL particles are degraded in a lysosome to 
amino acids, fatty acids, and CE, which are degraded by lysosomal lipase to cholesterol 
and fatty acids. Genetic defects in the LDL pathway lead to increased plasma levels of 
LDL, such as in familial hypercholesterolemia. The cholesterol released from the 
hydrolyzed LDL then acts in a negative feedback manor by reducing the amount of LDL 
receptors on the hepatocyte membrane, increasing the activity of cholesterol 
acyltransferase (ACAT), and decreasing the activity of HMGCA Reductase, a regulatory 
enzyme in the biosynthesis of cholesterol, through the sterol regulatory element-binding 
protein (SREBP) pathway. (Image taken from Goldstein, 2010).  
 
The number of LDL receptors available on hepatocytes is primarily regulated by 
the amount of free intracellular cholesterol in an attempt to prevent too much cholesterol 
from entering the cell (Feingold et al., 2018).  Sterol regulatory element binding proteins 
(SREBPS) are transcription factors that work to increase the expression of LDL receptors 
and other genes promoting cholesterol and fatty acid metabolism (Feingold et al., 2018).  
If cholesterol levels in the cell are too high, inactivated SREBPS stay in the endoplasmic  
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reticulum and are unable to travel to the Golgi apparatus to be cleaved into the active 
transcription factors which travel to the nucleus to promote LDL receptor gene 
expression (Feingold et al., 2018).  
 
Atherosclerosis and Familial Hypercholesterolemia 
LDL- C is commonly referred to as “bad cholesterol” as it carries approximately 
60-70% of the body’s plasma cholesterol to deposit in peripheral tissues (Kumar et al., 
2015). Many studies have shown a positive link between high circulating LDL-C causing 
CHD and ASCVD compared to moderate circulating levels, as shown in Figure 4 
(Ferenece et al., 2017; Grundy et al., 2004).  Over the past two decades, statin trials have 
shown the clinical benefit of lowering LDL-C levels to 70 mg/dL to directly reduce 
cardiovascular events (Cannon et al., 2015).  In 2015, the IMPROVE-IT trial 
demonstrated that ezetimibe added to moderate-intensity statins led to an even further 
reduction in LDL-C levels (LDL-C below 55 mg/dL), and reduced cardiovascular events 
even further compared to statin therapy alone (Cannon et al., 2015).  
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Figure 4. Log-linear relationship of serum LDL cholesterol concentrations to 
coronary heart disease risk.  Serum LDL-C levels are correlated with coronary heart 
disease risk over a wide range of values. For every 30 mg/dL increase in LDL-C, the 
relative risk for coronary heart disease increases by 30%  (Taken from Grundy et al., 
2004).  
 
Cardiovascular disease accounts for 31% of all deaths worldwide, and in the 
United States, cardiovascular disease kills more than the next two conditions, cancer and 
chronic lower respiratory disease, combined (Doonan et al., 2018). The AHA estimates 
that 1 in 3 people in the United States will be affected by cardiovascular disease in their 
lifetime (Doonan et al., 2018). The most prevalent form of cardiovascular disease is 
coronary artery disease, (CAD) representing approximately 45% of all cases, followed by 
stroke, representing 16.5% of all cases (Doonan et al., 2018). Both CAD and stroke are 
conditions directly caused by atherosclerosis, a chronic disorder that underlies coronary, 
cerebral, and peripheral vascular disease  (Kumar et al., 2015). 
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In ASCVD, CE accumulate in the endothelium, thickening the artery wall and 
reducing or blocking blood flow, leading to complications such as myocardial infarction, 
ischemic heart disease, or stroke (Kumar et al., 2015).  Risk factors for developing 
atherosclerosis are both modifiable (such as cigarette smoking, diabetes, inflammation, 
hypertension, and hyperlipidemia) as well as non-modifiable (genetic abnormalities, male 
gender, increasing age) (Kumar et al., 2015). The INTERHEART study, an international 
case-controlled study looking at 30,000 patients, found that out of nine easily measured 
and modifiable risk factors for a myocardial infarction, LDL accounted for 50% of the 
population attributable risk, followed next by smoking at 36% (Yusuf et al., 2014). 
Atherosclerosis is initiated by endothelial injury, due to inflammation within lipid 
filled plaques at sites prone to hemodynamic disturbance (Kumar et al., 2015). 
Lipoproteins, mostly LDL, enter the damaged endothelium and are oxidized, which 
activates the endothelial cells to undergo an inflammatory response, causing monocytes 
to enter and aggregate in the intima (Lu et al., 2015). Factor release from the leukocytes 
then causes smooth muscle cell proliferation, which converts the fatty streak into a 
mature atheroma (Kumar et al., 2015). The monocytes then convert into macrophages 
and internalize oxidized LDL via scavenger receptors, themselves becoming foam cells 
(Lu et al., 2015). Smooth muscle then migrates into the plaque, helping to form a fibrous 
cap to cover the plaque (Lu et al., 2015). Atherosclerotic plaques consist of a necrotic 
center of cholesterol, foam cells, and calcium, as well as a fibrous cap consisting of 
smooth muscle cells, macrophages, foam cells, collagen and lymphocytes (Kumar et al., 
2015). 
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Atherosclerotic plaques accumulate in blood vessels, especially medium and large 
arteries, thickening the wall and reducing or blocking blood flow (Lu et al., 2015).  When 
the cap ruptures, the acute reaction between the ruptured cap and the blood can cause a 
thrombotic event (Kumar et al., 2015).  If limited, the vessel may be able to heal itself 
and the clotting doesn’t obstruct the vessel, which would be a minimal event (Kumar et 
al., 2015). However, a ruptured cap completely blocking a vessel in the heart or brain 
leads to a myocardial infarction or stroke, respectively (Kumar et al., 2015). In addition, 
atherosclerosis may cause vessel wall remodeling after injury and possible aneurysm 
formation (Kumar et al., 2015). Increased LDL-C has been demonstrated to increase 
atherosclerosis-related cardiovascular events while increases in HDL-C levels have been 
demonstrated to reduce atherosclerosis (Lu et al., 2015). 
Familial hypercholesterolemia is an autosomal dominant genetic disorder caused 
by mutations that lead to an increase in total plasma cholesterol, LDL-C, and greatly 
accelerated atherosclerosis and heart disease (Kumar et al., 2015). Mutations in the genes 
LDLR (85-90% of cases), ApoB (5-10% of cases), LDLRAP1 (<5% of cases), as well as 
PCSK9 (<5% of cases) have been deduced to result in FH (Kumar et al., 2015). 
Approximately 70% of plasma LDL is cleared by the LDL receptor, so as a result of the 
receptor defect, patients with heterozygous FH have a two- fold to three-fold elevation in 
their plasma cholesterol levels due to the inability of the liver to clear LDL, while 
homozygous FH patients have a five-fold to six-fold increase in plasma cholesterol levels 
(Kumar et al., 2015).  Therefore, FH patients have chronically severely elevated LDL 
concentration in the plasma, commonly above 200 mg/dL (Kumar et al., 2015).  Due to 
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the severe dyslipidemia, FH patients are at high risk for developing atherosclerosis as 
well as skin xanthomas, which are firm, painless, red-yellow nodules on the skin in 
extensor surfaces of joints and pressure areas of the body of accumulated lipid and 
cholesterol (Poonia et al., 2013). Table 2 includes diagnostic categories for determining 
if a patient has either heterozygous or homozygous FH.  
Table 2: Adult Familial Hypercholesterolemia Diagnostic Categories* 
HeFH 
LDL-C ≥ 190 mg/dL and with 1 first- degree relative 
affected or with premature CAD or with genetic testing 
positive for a LDL-C raising gene defect  
HoFH 
LDL-C ≥ 400 mg/dL and 1 or both parents with FH, genetic 
testing positive for a LDL-C raising gene defect  
OR  
Autosomal-recessive FH if LDL-C> 560 mg/dL or LDL-C > 
400 mg/dL with aortic valve disease or xanthomata at <20 
years old 
Family history of FH 
LDL-C level not a clinical criteria, but is determined by 
having a first-degree relative with FH 
 
*For Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial 
Hypercholesterolemia (HoFH), and a family history of FH, diagnostic criteria are given. 
(Table recreated from Kumar et al., 2015. 
 
 
Cholesterol Level Recommendations  
According to the 2013 American College of Cardiology (ACC) and American 
Heart Association (AHA) guidelines, approximately 48.6% of American adults over the 
age of 40 are eligible for statin therapy (Benjamin et al., 2018). However, the foundation 
for reducing the risk of ASCVD and other cardiovascular events lies in lifestyle 
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modifications such as following a heart-healthy diet, regular exercise, maintaining a 
healthy weight, and avoiding tobacco products (Benjamin et al., 2018). Patients should 
make these lifestyle changes both before or in conjunction with a cholesterol-lowering 
therapy for maximal benefit (Benjamin et al., 2018). 
In 2013, the ACC and AHA deviated from the previous guidelines, the Adult 
Treatment Panel III Guidelines, in regards to the treatment of cholesterol to reduce 
atherosclerotic cardiovascular risk (Stone et al., 2014). The new guidelines identify an 
additional 13 million Americans that are now eligible for statin therapy (Stone et al., 
2014).  The expert panel decided to move away from determining a specific goal for 
LDL-C levels, opting rather to identify four groups in which ASCVD risk reduction from 
statin therapy clearly outweighed the risk of adverse events.  (Stone et al., 2014). This 
change was implemented due to the thought that a “treating to goal” mentality may result 
in treatment with suboptimal statin intensity or result in adding non-statin therapy in the 
absence of evidence that it improves outcomes (Stone et al., 2014). The four identified 
treatment groups and treatment recommendations are detailed in Table 3.  The primary 
prevention population is defined as those who have not had a cardiovascular event, while 
the secondary prevention population is defined as those who have had cardiovascular 
events such as an acute coronary syndrome, a history of myocardial infarction, angina, 
coronary revascularization, stroke, transient ischemic attach, or peripheral arterial disease 
of atherosclerotic origin (Stone et al., 2014). 
Table 3: The four major statin benefit groups with ACC/AHA treatment 
recommendations* 
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Benefit Group Major Recommendations 
 
Secondary prevention in patients with 
clinical ASCVD 
1. If patient ≤ 75 years old, consider a high 
intensity statin 
2.  If patient > 75 years old, consider a 
moderate-intensity statin 
 
 
Primary prevention in individuals with 
LDL-C ≥ 190 mg/L 
1. Consider high intensity statin therapy to 
lower LDL-cholesterol by 50% 
2. Consider combining statin with additional 
therapy to lower LDL- cholesterol 
3. Screen immediate family members to 
determine if others would benefit from lipid 
lowering therapy 
Primary prevention in patients with 
diabetes 40-75 years old with LDL-C 
70-189 mg/dL 
1. Consider a moderate- intensity statin 
2. If at high risk for ASCVD (10 year risk ≥ 
7.5%, consider high intensity statin) 
 
 
 
Primary prevention in patients without 
diabetes and 10 year ASCVD risk 
greater than or equal to 7.5%, 40-75 
years old who have LDL-C of 70-189 
mg/dL 
1. Estimate 10-year ASCVD risk: 
    If ≥7.5%, moderate- or high-intensity statin 
    If ≥5 to <7.5%, moderate-intensity statin. 
2.  In individuals with 10-year ASCVD 
risk <5%, or age <40 or >75 years, 
individualize statin therapy 
3. Before beginning statin therapy, discuss with 
the patient the potential for ASCVD risk-
reduction benefits and adverse effects and 
drug–drug interactions. Also consider patient 
preferences before starting statin therapy. 
 
*In 2013, the ACC and AHA modified the cholesterol treatment guidelines, creating four 
groups that would benefit the most from statin therapy. (Table modified from Stone et al., 
2013). 
 
The ACC and AHA expert panel was intentionally broad when discussing 
guidelines for clinicians to follow when treating high-risk patients who could not tolerate 
statin therapy due to severe adverse events such as hepatotoxicity and muscle problems 
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(Lloyd-Jones et al., 2017).  Statin intolerance can be either complete (intolerant of all 
statins at any dose) or partial (intolerant to only some statins at some doses (Fitchett et 
al., 2015).  Up to 15% of patients taking statins develop statin intolerance due to adverse 
events such as muscle aches, pains, myalgias, or elevated markers of liver or muscle 
function (Fitchett et al., 2015).  These symptoms disappear when the patient stops statin 
therapy (Fitchett et al., 2015).  Some patients can tolerate statin therapy, but do not 
exhibit the desired effects of lowered LDL-C levels, possibly due to genetic variations in 
genes related to statin metabolism such as intestinal P-glycoprotein, organic anion 
transporter 2, coenzyme Q10, or cytochrome P450 3A4 (Doonan et al., 2018). Only 21% 
of patients achieve guideline recommended LDL-C levels while on statin therapy alone 
(Boekholdt et al., 2014). Additionally, only 44% of patients achieved their target LDL-C 
level when prescribed combination therapy (ezetimibe and a statin) (Bandyopadhyay et 
al., 21018). To determine if a patient is responsive to statin therapy, an initial fasting lipid 
panel (TC, triglycerides, HDL-C, and LDL-C) should be compared to a second fasting 
lipid panel 4 to 12 weeks after starting statin therapy (Lloyd- Jones et al., 2017).  
For patients who are stain intolerant, it is recommended that clinicians continue to 
emphasize lifestyle modifications, as well as consider prescribing a non-statin cholesterol 
lowering therapy that has been shown to provide risk-reducing benefits that outweigh 
potential adverse effects and drug-drug interactions (Lloyd-Jones et al., 2017). Examples  
of different therapies to lower LDL-C levels are outlined in Figure 5.  Notably, patients 
are often prescribed ezetimibe, which lowers intestinal absorption of cholesterol by 
blocking the Niemann-Pick C1-Like 1 protein, and is commonly used as a placebo in 
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clinical trials investigating LDL-C lowering therapies (Savarese et al., 2015).  While 
ezetimibe has been shown to lower LDL-C by an additional 20-25%, there is a lack of 
efficacy data as well as safety concerns about the therapeutic (Savarese et al., 2015).   
 
Statin Therapy and PCSK9 Inhibitors 
The mechanism of action of statins is to competitively inhibit the rate-limiting 
enzyme for endogenous cholesterol biosynthesis, HMGCR, preventing the formation of 
mevalonate, a cholesterol precursor (Doonan et al., 2018). By inhibiting HMGCR, statins 
result in reduced cholesterol biosynthesis in hepatocytes for export in VLDL as well as an 
increase in LDL receptor levels due to stimulated SREBP, which promotes LDLR 
transcription (Doonan et al., 2018). Statins have other effects in the body; for instance, 
statins can increase circulating PCSK9 levels (Lin et al., 2018). Notably, a study by 
Caresky et al. found that atorvastatin increased PCSK9 levels by 34% in patients (Lin et 
al., 2018).  This is significant as it could be an explanation for why increasing doses of 
some statins, such as atorvastatin, fail to proportionally lower plasma LDL-C levels (Lin 
et al., 2018). 
  Statins function by a dose-dependent effect: doubling a statin dose reduces LDL-
C level by 6% (Illingworth et al., 2017).  Although statins are a well-established first line 
therapy to reduce the amount of cholesterol synthesized in the body, statins are not 
without drawbacks (Doonan et al., 2018). As detailed above, statins are not universally 
effective; some patients do not respond to statins and others are statin intolerant due to 
significant adverse effects such as elevated hepatic transaminases, myalgias, myositis, 
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and rhabdomyolysis (Kashani et al., 2006). Additionally, a meta-analysis found a 9% 
increase in diabetes developed by patients on statins (Doonan et al., 2018). 
 
 
 
Figure 5: Additional therapies to lower plasma LDL levels. Statins competitively 
inhibit HMG-CoA Reductase to block endogenous cholesterol synthesis in the liver. Bile 
acid sequestrates (resins) act to bind bile acids in the intestine and block their 
reabsorption. This effectively decreases the bile acid pool, increasing the conversion of 
cholesterol to bile acids in hepatocytes, increasing the need for cholesterol in hepatocytes. 
This need then increases the activity of HMG Co-A Reductase as well as up regulates 
LDL receptors on the hepatocyte, clearing more LDL from the plasma. Another non-
statin therapy includes Ezetimibe, which inhibits dietary cholesterol absorption in the 
small intestines. In addition, ileal bypass surgery lowers LDL-C by shortening the length 
of the small intestine. Finally, PSCK9 Inhibitors increase the amount LDL receptors on 
hepatocytes, increasing LDL-C clearance (Image taken from Ference et al., 2017). 
PCSK9 is a vital protein in the role of lysosomal degradation of the LDL receptor 
(Hovingh et al., 2014).  Abifadel and coworkers discovered PSCK9 in 2003 when by 
identifying a gain of function mutation in PCSK9 in patients with FH (Hovingh et al., 
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2014).  Located on chromosome 1, the PCSK9 gene codes for the serine protease 
expressed mainly in the liver, intestine, and kidney (Farnier et al., 2014). The protein is 
synthesized as a 692 amino acid glycoprotein, and then the zymogen undergoes 
processing in the endoplasmic reticulum to yield a 14kDa prodomain and a functional 
63kDa PCSK9 (Hovingh et al., 2014).  
Normally, LDL binds to the LDL receptors on the hepatocyte membrane and then 
the entire complex undergoes endocytosis (Dixon et al., 2017). PCSK9 binds to the LDL 
receptor with LDL, and the complex is internalized into the hepatocyte and degraded by 
lysosomes (Dixon et al., 2017). Since the LDL receptor is metabolized, it is then unable 
to be recycled back to the hepatocyte membrane to clear more LDL from the circulation 
(Dixon et al., 2017). A gain of function mutation of PCSK9 will lead to an elevated LDL 
level and cardiovascular disease, as seen in patients with FH (Dixon et al., 2017). A loss 
of function mutation of PCSK9 will lead to a more LDL receptors on the hepatocyte level 
to clear more LDL from the plasma resulting in a reduced risk for cardiovascular disease 
(Dixon et al., 2017). A Danish study found that the loss of function mutation in PCSK9  
accounted for a 12% reduction in LDL-C and a 28% reduction in cardiovascular disease 
risk (Farnier et al., 2014).  
 
 
PUBLISHED STUDIES 
  The following literature review will first analyze evolocumab’s development by 
AMGEN and safety ratings in humans with dyslipidemia. Next, the efficacy and clinical 
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utility of the PCSK9 inhibitor will be analyzed, along with its ability to reduce 
cardiovascular events as shown by the recent breakthrough FOURNIER clinical trial. 
Additionally, a review of cost-effective assessments of evolocumab will provide insight 
into evolocumab’s present place in lipid lowering therapy. The role of evolocumab in 
today’s society as well as future implications will also be explored. 
 
Evolocumab: safety, tolerability, and efficacy in humans  
Repatha, or generic name Evolocumab, was developed and manufactured by 
AMGEN Incorporated and was approved by the Food and Drug Administration (FDA) on 
August 27, 2015 (FDA, 2015).  Evolovumab is a human monoclonal immunoglobulin G2 
against human PCSK9 indicated to lower LDL-C in adult patients who have, despite 
dietary and lifestyle changes and maximally tolerated statin dose, continued 
suboptimal lipid levels with either ASCVD or HeFH (FDA, 2015). Evolocumab was not 
the first PCSK9 inhibitor on the market; the FDA approved Alicoumab, known by its 
brand name Praluent, on July 24, 2015 (FDA, 2015).   
Two Evolocumab Phase I studies evaluated the safety, tolerability, 
pharmacokinetics, and pharmacodynamics of AMG 145, (the development name for 
evolocumab), on healthy adult humans (Phase 1a) and adults with hypercholesterolemia 
on statin therapy (Phase 1b) (Dias et al., 2012).  In the Phase 1a trials, AMG 145 reduced 
LDL-C levels up to 64% compared to the placebo after one dose, and AMG 145 reduced 
LDL-C levels by 81% with continued therapy (Dias et al., 2012). Pharmacodynamic 
analysis revealed that single administration of AMG 145 decreased mean LDL-C with a 
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return to baseline levels within 71 days (Dias et al., 2016). Due to the structure of AMG 
145, a human monoclonal antibody, the best route of administration for highest 
bioavailability is through subcutaneous injection to the thigh, abdomen, or upper arm 
(FDA, 2015). In the safety analysis, no significant adverse events were reported 
throughout the duration of the study, and adverse event incidences were similar in 
treatment versus placebo groups (Dias et al., 2016). AMG 145 then continued to Phase II 
trials to further evaluate the drug’s safety and efficacy. 
The PROFICIO trial pooled data from 4 randomized, twelve week, placebo-
controlled phase II trials (MENDEL, LAPLACE-TIMI 57, RUTHERFORD, and 
GAUSS) to better assess the safety, tolerability, and efficacy of AMG 145 in over 1300 
patients (Stein et al., 2014). The four phase II studies analyzed in the PROFICIO trial are 
detailed in Table 4 below. 
 
 
 
 
 
 
 
Table 4. Phase II AMG 145 studies analyzed in the PROFICIO clinical study. 
Study Name 
Number of 
Patients 
Background 
Lipid Therapy 
Length 
(weeks) 
Dosing Study Aim 
LAPLACE-
TIMI 
631 Statin (+/- 
ezetimibe) 
12 70, 105, 140 mg Q2W 
Evolocumab or placebo 
Combination 
therapy with 
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OR 
280, 350, 420 mg Q4W 
Evolocumab or placebo 
statins 
RUTHERFORD 167 Statin (+/- 
ezetimibe) 
12 350, 420 mg Q4W 
Evolocumab or placebo 
HeFH 
GAUSS 157 Non ezetimibe 
lipid lowering 
therapy 
12 280, 350, 420 Q4W 
Evolocumab  
OR 
Ezetimibe 10 mg+ SC 
placebo Q4W 
OR 
Ezetimibe 10 mg + 
Evolocumab 420mg Q4W  
Statin 
intolerant 
patients 
MENDEL 406 No background 
anti-lipid 
therapy 
12 70, 105, 140 mg Q2W 
Evolocumab or placebo  
OR 
 280, 350, 420 mg Q4W 
Evolocumab or placebo 
Stand-alone 
monotherapy 
 
Study name, patient number, background lipid therapy, study length, dosing, and aim of 
the four AMG 145 clinical trials detailed in the PROCIFIO study. Q2W, every 2 weeks; 
Q4W, every 4 weeks; GAUSS (Goal Achievement After Utilizing an Anti-PCSK9 
Antibody in Statin-Intolerant Subjects); LAPLACE-TIMI 57 (LDL-C Assessment with 
PCSK9 Monoclonal Antibody Inhibition Combined with Statin Therapy); MENDEL 
(Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently 
Not Receiving Drug Therapy for Easing Lipid Levels); RUTHERFORD (Reduction of 
LDL-C With PCSK9 Inhibition in HeFH Disorder) (Table taken from Stein et al., 2014). 
 
 
 
PROFICIO trial safety assessments show that adverse events were reported in 
56.8% of evolocumab treated groups and 49.2% of placebo groups (Stein et al., 2014).  In 
order of highest prevalence, nasopharyngitis, upper respiratory infection, headache, 
diarrhea, myalgia, and back pain were the adverse events most commonly reported in the 
evolocumab treatment group (Stein et al., 2014).   Serious adverse events were reported 
in 2% of evolocumab treated groups and 1.2% of placebo treated groups, and 
investigators considered none of the events to be treatment related (Stein et al., 2014).  
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The tolerability of subcutaneous administration was also assessed with injection 
site reactions reported in 4.1% of evolocumab patients and in 3.3% of placebo patients 
(Stein et al., 2014).  This reaction rate is significantly lower than mipomersen (an Apo B 
antisense molecule), another FDA approved subcutaneous administered lipid lowering 
therapy, which caused injection site reactions in 92% of patients (Stein et al., 2014).  The 
only contraindication on the FDA label for evolocumab is in patients with a history of a 
serious hypersensitivity reaction, such as a rash or urticaria, to evolocumab (FDA, 2015).  
In terms of LDL-C reduction, the PROFICIO trial found mean percentage 
reduction levels ranging from 40.2% to 59.3% among all evolocumab groups compared 
to placebo, as shown in Figure 6 (Stein et al., 2014).  The greatest decrease in LDL-C 
levels was seen with the 140 mg dose Q2W (Stein et al., 2014).  Additionally, significant 
reductions in Apo B, non HDL-C, triglycerides, and lipoprotein (a) were observed (Stein 
et al., 2014).  The safe and effective results of these studies allowed evolocumab to 
continue to larger, longer studies in Phase III clinical trials.  
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Figure 6.  Evolocumab Q2W (Figure A) and Q4W (Figure B) lowers LDL-C 
significantly from baseline levels compared to placebo.  Data complied in the 
PROFICIO study taken from four phase II evolocumab 12-week clinical trials shows 
percentage changes from baseline in LDL-C levels. (Figure taken from Stein et al., 2014) 
 
The landmark Evolocumab outcomes study, FOURIER, an international, double 
blind, randomized, placebo-controlled trial, was designed to evaluate cardiovascular risk 
reduction by dramatically lowering LDL-C (Sabatine et al., 2017). A total of 27,564 
  26
patients met the following study criteria: age greater than or equal to 40 and less than or 
equal to 85, patient history of a prior myocardial infarction, prior stroke, or symptomatic 
peripheral arterial disease, fifteen weeks on a stable background lipid-lowering therapy 
such as a statin with or without ezetimibe, and LDL-C > 70 mg/dL or non HDL-C > 100 
mg/dL (Sabatine et al., 2017). Many patients who enrolled in the study are patients that 
are at high risk for another cardiovascular event; the mean baseline LDL-C was 92 mg/dL 
and 70% of patients were on high-intensity statins (Sabatine et al., 2017).  Patients were 
randomized 1:1 to either evolocumab 140 mg Q2W or 40 mg Q4W and a statin, or 
placebo and a statin (Sabatine et al., 2017).  The primary efficacy end point of the study 
was “the composite of cardiovascular death, myocardial infarction, stroke, hospitalization 
for unstable angina, or coronary revascularization” (Sabatine et al., 2017). 
After 48 weeks, the evolocumab treatment group had LDL-C levels reduced to 
≤70 mg/dL in 87% of patients, ≤ 40 mg/dL in 67% of patients, and ≤ 25 mg/dL in 42% of 
patients, compared with the placebo group, which was 18%, 0.5%, and less than 0.1% 
respectively (Sabatine et al., 2017). These data are sown in Figure 7. Additionally, after 
48 weeks, the evolocumab treatment group had non HDL-C levels reduced by 52% and 
Apo B levels reduced by 49% (Sabatine et al., 2017).  
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Figure 7. Evolocumab lowers LDL-C levels significantly compared to placebo. After 
48 weeks, evolocumab lowered LDL-C by a mean of 56 mg/dL compared to placebo. 
(Image taken from Sabatine et al., 2017). 
 
 
Importantly, the addition of evolocumab with a statin was shown to reduce the 
risk of the primary composite endpoint of cardiovascular death, myocardial infarction, 
stroke, hospitalization for unstable angina, or coronary revascularization by 15% as 
shown in Figure 8 (Sabatine et al., 2017).  These results show that patients with ASCVD 
will have reduced morbidity and mortality by lowering LDL-C cholesterol levels with 
evolocumab (Sabatine et al., 2017). 
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Figure 8. Incidence of cardiovascular events in the FOURNIER trial. (Table taken 
from Sabatine et al., 2017). 
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Cost-Effectiveness Assessments of Evolocumab 
 
According to the AHA, cardiovascular disease costs more than any other ailment 
in the United States, estimating an annual cost of over $650 billion for cardiovascular 
disease in 2011 (Mozaffarian et al., 2015).  These costs are projected to double by the 
year 2030 despite widespread statin therapy (Mozaffarian et al., 2015). Therefore, the 
cost-effectiveness of new therapies aimed to lower the risk of cardiovascular disease has 
become increasingly important as healthcare costs rise. 
The PCSK9 inhibitor evolocumab has been shown to lower plasma LDL-C levels 
and risk for cardiovascular events in conjunction with other lipid lowering therapies.  
Evolocumab is safe and effective, but its high cost may limit its routine use (Turgeon et 
al., 2018). The yearly cost of evolocumab in the United States was $14,350 in 2015 (Kazi 
et al., 2016). In comparison, the cost of a generic statin, simvastatin, according to the Red 
Book was $11 per year per patient in 2015 making evolocumab significantly more 
expensive (Luo and Kesselheim, 2015). However, studies to determine the cost 
effectiveness of evolocumab have found differing conclusions.  
Cost-effective analyses examine a particular therapy by asking, “How much 
health benefit do we get for our money?” (Owens et al., 1999). There are two definitions 
from the World Health Organization (WHO) and the ACC/AHA that are commonly used 
as cost-effective thresholds, or the amount of money society is willing to spend to gain 
one year of life (Gandra et al., 2016). These definitions are detailed in Table 5, which 
portrays the thresholds in terms of cost per quality-adjusted life year (QALY) (Gandra et 
al., 2016). The National Institute of Health and Clinical Excellence (NICE) has defined 
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QALY as a “measure of the state of health of a person in which the benefits, in terms of 
length of life, are adjusted to reflect the quality of life” (Owens et al., 1999). QALYs are 
calculated by estimating the possible years of life left for a patients following a treatment 
and weighting each year with a quality-of-life score (Owens et al., 1999).  This quality of 
life score is from 0 to 1; absence of life is worth zero QALYs and a one-year of perfect 
health is worth 1 QALY (Owens et al., 1999). Cost-effectiveness ratio is most effective 
when expressed as dollars per QALY, as this allows one to compare the efficiency of 
interventions for different conditions using the same units (Owens et al., 1999).   
 
Table 5. Cost-effective threshold definitions from the WHO and AHA/ACC 
WHO thresholds based on 2014 US gross domestic product per capita 
Highly cost-effective < $55,000/ QALY 
Cost-effective $55,000- $165,000/ QALY 
Not cost effective > $165,000/ QALY 
 
AHA/ACC thresholds based on level of value to society 
High < $50,000/ QALY 
Intermediate $50,000 to < 150,000/ QALY 
Low >$150,000/ QALY 
 
*Thresholds defined in terms of United States dollar cost per QALY. (Table taken from 
Gandra et al., 2016).  
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To compare the cost of standard of care to standard of care plus the treatment, the 
incremental cost-effectiveness ratio (ICER) is used to summarize the cost-effectiveness 
of the intervention (ICER) (Gandra et al., 2016). ICER is defined as the difference in cost 
between two possible interventions, divided by the difference in their effect (Gandra et 
al., 2016). In this study, ICER is the difference in cost between evolocumab added to 
standard of care and just standard of care divided by the difference in their effect in terms 
of LDL-C lowering (Gandra et al., 2016).  This study determined ICERs of $75,863/ 
QALY gained in HeFH, $141,699/ QALY gained in ASCVD, and $100,309/ QALY 
gained in patients with ASCVD with statin intolerance (Gandra et al., 2016). These 
ICERS meet the WHO definition of cost effective and the ACC/AHA definition for 
high/intermediate thresholds (Gandra et al., 2016). Ultimately, the study found 
evolocumab to be more cost-effective in patients with HeFH than ASCVD or ASCVD 
with statin intolerance (Gandra et al., 2016).  
Others have concluded that Repatha is not cost effective in patients with HeFH or 
ASCVD, and believe it will add to increasing health care costs in the United States (Kazi 
et al., 2016; Fonarow et al., 2017).  The following studies argue that reducing the annual 
drug price is necessary to meet cost effective thresholds; otherwise, the drug will result in 
an increase US health care spending by about $120 billion (Kazi et al., 2016).  
In 2016, Dhruv Kazi and coworkers found that evolocumab therapy in patients 
with both HeFH and ASCVD does not meet acceptable cost-effective thresholds (Kazi et 
al., 2016).   The study was designed using the Cardiovascular Disease Policy Model, and 
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evaluated statin therapy compared with addition of either ezetimibe or PCSK9 inhibitors 
(Kazi et al., 2016).   
The results found that adding PCSK9 inhibitors to statins in HeFH prevented 
316,300 major adverse cardiovascular events (MACE), defined as cardiovascular death, 
nonfatal myocardial infarction, or stroke (Kazi et al., 2016).  This would cost $503,000 
/QALY gained (Kazi et al., 2016). In patients in ASCVD, adding a PCSK9 inhibitor to 
statins would prevent 4.3 million MACE and cost $414,000/ QALY gained, which is 
significantly over the willingness to pay threshold of $100,000/ QALY gained (Kazi et 
al., 2016). To be cost effective at the willingness to pay threshold of $100,000/ QALY, 
evolocumab’s price would need to be lowered by 70% to $4,536 annually in the United 
States (Kazi et al., 2016).  Figure 7 shows the proportion of optimal simulations as a 
function of drug price in the United Kingdom, Austria, Finland, and United States, with 
the United States having the highest price out of all the countries (Kazi et al., 2016).  At 
2015 prices, evolocumab was estimated to increase cardiovascular care costs by $29 
billion over five years if used in every eligible patient in the United States (Kazi et al., 
2016).  
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Figure 11. At 2015 prices for evolocumab and a threshold of $100,000 per QALY 
gained, evolocumab is not cost effective in FH (a) or ASCVD (b). The price of 
evolocumab for one year in the United Kingdom, Austria, and Finland is $6427, $8110, 
and $8700 respectively. This is in comparison to the US price of $14100 annually. 
(Image taken from Kazi et al., 2016).  
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Evolocumab is currently approved for use in 50 countries including the United 
States, Japan, Canada, and the 26 members of the European Union (Lee et al., 2018).  
Countries outside of the United States have also agreed that although evolocumab 
treatment is effective in lowering cardiovascular events, the drug is not cost effective in 
other health care systems. In Spain, evolocumab’s annual cost is 11 134.78€ compared to 
the standard treatment (statins plus ezetimibe) cost of 393.83€ (Olry de Labry Lima et al., 
2018). The ICER ratio was > 600 000€ (Olry de Labry Lima et al., 2018).  In Canada, 
evolocumab costs $7500 annually and was still deemed to be not cost effective, and for 
the drug to have a 50% probability of being cost effective. It was found that the price 
would need to be lowered to $1200 per year and $2300 per year in a willingness to pay 
threshold of $50,000/ QALY gained and a willingness to pay threshold of $100,000/ 
QALY gained, respectively (Lee et al., 2018).  
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DISCUSSION 
 
 
 Cardiovascular disease is the number one killer in the United States, and accounts 
for 31% of all deaths worldwide. Over 45% of those deaths are due to coronary artery 
disease, a direct result of atherosclerosis.  Atherosclerosis is a process where plaques of 
fatty material build up in an artery’s wall. Atherosclerosis is directly correlated with 
elevated LDL levels as LDL is deposited in the artery’s wall and causes an inflammatory 
immune response which triggers the creation of foam cells and fatty plaques which can 
rupture, directly causing cardiovascular events such as myocardial infarction or stroke.  
Recently, treatment guidelines for treating hyperlipidemia have changed.  The 
new AHA/ACC treatment guidelines identify an additional 13 million Americans that are 
now eligible for statin therapy based on four categories of patients who would receive the 
most benefit from a lipid lowering therapy.  Statins, functioning as a HMGCR inhibitor, 
are the first drug of choice to treat elevated LDL-C and act by inhibiting cholesterol 
biosynthesis in hepatocytes. However, some patients are statin resistant or statin 
intolerant and either do not respond to the therapy or do not benefit from the therapy 
because of significant adverse side effects including hepatic dysfunction and severe 
myalgias.  Additionally, patients with FH, an autosomal dominant genetic disorder 
caused by mutations that lead to an increase in total plasma cholesterol require additional 
lipid lowering therapies as they are prone to greatly accelerated atherosclerosis and heart 
disease. 
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 A new therapy approved in 2015 to dramatically reduce LDL-C levels is a human 
monoclonal antibody, Evolocumab, developed by AMGEN. Evolocumab binds to 
PCSK9 and inhibits circulating PCSK9 from binding to the LDL receptor, preventing 
PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver 
cell surface. By inhibiting the LDL receptor from binding to PCSK9, evolocumab 
increases the amount of LDL receptors available to clear LDL from the blood, effectively 
lowering LDL-C levels.  Evolocumab is FDA indicated for adults, in addition to diet and 
maximally tolerated statin therapy for patients with HeFH or ASCVD who are not 
meeting acceptable LDL-C level. Additionally, evolocumab is FDA approved for adults 
with HoFH, in addition to diet and other lipid lowering therapies such as statins and 
ezetimibe, to help further lower their LDL-C level.  
Clinical studies have shown evolocumab is safe and effective in patients. 
Evolocumab was determined to be safe and well tolerated, as the only significant 
contraindication is an allergic reaction to the drug.  However, some patients reported an 
injection site reaction as evolocumab is administered as an injection to the leg, stomach 
or arm due to its structure as a monoclonal antibody.  The Phase II clinical trial “Program 
to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In 
Different Populations (PROFICIO), pooled data from 4 randomized, twelve week, 
placebo-controlled phase II trials (MENDEL, LAPLACE-TIMI 57, RUTHERFORD, and 
GAUSS) to assess the safety, tolerability, and efficacy of Evolocumab in over 1,300 
patients.  In the PROFICIO study, it was found that Evolocumab reduced LDL-C levels 
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by 47-56% compared to placebo on top of maximally tolerated statins and a proper 
diet regiment.   
In the breakthrough clinical trial, further Cardiovascular Outcomes Research 
With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER), after 48 weeks, 
the evolocumab treatment group’s LDL-C levels reduced to ≤70 mg/dL in 87% of 
patients, compared with the placebo group, in which only 18% achieved that 
traditionally appropriate LDL-C level. In addition to lowering LDL-C levels, 
evolocumab reduces morbidity and mortality caused by cardiovascular events from 
dyslipidemia, as shown in the FOURNIER trial.  The trial reported a 15% reduction 
in the risk of death, MI, stroke, hospitalization for angina or revascularization 
compared to placebo. This study has huge implications for the future of evolocumab 
as it was shown to save lives and prevent a reduction in quality of life due to 
cardiovascular disease in patients with FH and ASCVD. However, clinicians were 
hoping the outcomes trial would show evolocumab to be a “blockbuster drug” 
worthy of its expensive price tag of over $14,000 annually.  
Evolocumab’s place in therapy for the treatment of hypercholesterolemia is 
controversial due to the high annual cost of $14,542 in the United States. In addition, one 
has to consider the impact the cost of the drug has on the healthcare system as a whole.  
Some studies found evolocumab would increase United States health care spending by 
over $120 billion. Furthermore, studies in Spain and Canada also found the drug to be not 
cost effective for their health care systems. Additional analysis shows that the drug is 
more cost effective in patients with HeFH compared to patients with ASCVD or patients 
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ASCVD who are unresponsive to statin therapy. It was determined that to be cost 
effective at the willingness to pay threshold of $100,000/ QALY for widespread use in 
the United States, significant cost reductions, as much as 70% of the current annual price 
($4,536 annually), are needed.  The use of Evolocumab in every eligible patient is 
discouraged due to the high costs associated with the therapy.    
Amgen faces competition as manufactures of other PCSK9 inhibitors, including 
Sanofi and Regeneron, have published their own cardiovascular outcomes studies with 
results similar to evolocumab.  These companies have also implied a willingness to 
reduce the cost of their PCSK9 inhibitors in certain high-risk patient populations, such as 
patients with a history of a myocardial infarction or stroke as well as high LDL levels 
despite statin therapy.  Ultimately, evolocumab is an effective, safe new therapy to 
significantly lower LDL levels in adult patients with FH and ASCVD unresponsive to 
statin therapy; however, in order for evolocumab to become a therapy for primary 
prevention of cardiovascular disease, the price needs to be significantly lowered to be 
cost-effective in the United States.  
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